2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2775 Contemporary outcomes of patients with light chain multiple myeloma receiving upfront autologous hematopoietic stem cell transplantation

Mousa Thalji, MD, Denai Milton2, Mark R. Tanner, PhD, MBA, CMPP3, Qaiser Bashir, MD4, Samer A Srour, MB ChB, MS5, Neeraj Saini, MD6, Paul Lin, MD, PhD7, Jeremy Ramdial, MD8, Yago Nieto, MD, Ph.D9, Guilin Tang, MD, PhD,FACMG10, Yosra M. Aljawai, MD MS11, Krina Patel Jr, MD, MSc12, Jing Christine Ye, M.D., MSc13, Mahmoud R. Gaballa, MD14, Sarvari V. Yellapragada, MD15, Partow Kebriaei, MD16, Sheeba Koshy Thomas, M.D.17, Robert Orlowski, MD, PhD18, Richard Champlin19, Elizabeth Shpall, MD20, Muzaffar Qazilbash, MD21, Oren Pasvolsky, MD22
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Background

Light chain multiple myeloma (LCMM) accounts for approximately 15–20% of all multiple myeloma (MM) cases and is characterized by a higher incidence of renal dysfunction. Although autologous hematopoietic stem cell transplantation (autoHCT) is the standard consolidative therapy for transplant-eligible patients with MM, it remains unclear whether LCMM independently influences outcomes following autoHCT in the contemporary treatment era. We evaluated treatment response and survival outcomes following upfront autoHCT in patients with LCMM and compared their outcomes to patients with non-LCMM MM.

Methods

We retrospectively analyzed 1,680 consecutive patients who underwent first autoHCT for MM between 2010 and 2021 at our institution, including 284 patients with LCMM. To minimize baseline differences, patients with LCMM were propensity score matched (2:1) with patients with non-LCMM based on age, transplant era, cytogenetic risk, IMS/IMWG high-risk disease, hematopoietic cell transplantation–comorbidity index (HCT-CI), induction regimen, conditioning regimen, and maintenance therapy to minimize baseline differences between groups. Outcomes included treatment response as well as progression-free survival (PFS), and overall survival (OS), which were estimated using the Kaplan-Meier method and assessed by Cox proportional hazards regression models. 

Results

Among 1,680 patients undergoing first autoHCT, 284 (17%) had LCMM and 1,396 (83%) had non-LCMM. Compared with the non-LCMM cohort, patients with LCMM had significantly higher rates of renal dysfunction (creatinine >2 mg/dL, 28% vs. 13%; P<0.001) and elevated LDH (24% vs. 16%; P=0.004) at diagnosis. For both LCMM and non-LCMM patients, bortezomib, lenalidomide and dexamethasone (VRD) was the most common induction regimen used (35% and 42%, respectively), while carfilzomib, lenalidomide and dexamethasone (KRD) (22% and 23%) was the next most common. Single-agent melphalan was used as conditioning in 84% of patients with LCMM and 79% of those with non-LCMM, while busulfan-melphalan was used in 11% and 16%, respectively (P=0.11). Age, race, cytogenetic risk, revised international staging system (R-ISS) stage, HCT-CI, and use of maintenance therapy were similar between groups. LCMM patients achieved significantly higher CR rates before autoHCT (24% vs. 13%; P<0.001), at day 100 after autoHCT (47% vs. 33%; P<0.001), and as their best overall response following autoHCT (65% vs. 57%; P=0.012). Median PFS was 50.0 months for LCMM and 48.1 months for non-LCMM patients (hazard ratio (HR), 0.96; 95% CI, 0.80–1.15; P=0.68), while median OS was 112.9 and 105.0 months, respectively (HR, 0.93; 95% CI, 0.72–1.20; P=0.57). Multivariable analysis demonstrated that LCMM was not independently associated with inferior PFS or OS. Instead, high-risk cytogenetics, elevated LDH, high-risk disease and failure to achieve CR after autoHCT were independently associated with inferior outcomes. In a propensity score-matched cohort of 283 patients with LCMM and 566 patients with IgG/IgA MM, survival outcomes were numerically shorter in the LCMM group, yet the difference in PFS (median 50.0 vs. 58.6 months; HR,1.08; 95% CI, 0.84–1.40; P=0.54), and the difference in OS (median 112.9 vs. 130.8 months; HR, 1.15; 95% CI, 0.79–1.68; P=0.47) both remained non-significant. 

Conclusion

In this large cohort of newly-diagnosed MM patients treated with upfront autoHCT in the era of novel anti-myeloma agents, patients with LCMM achieved deeper responses following autoHCT, despite presenting with some adverse clinical features.  In a propensity score-matched analysis, patients with LCMM had numerically shorter survival outcomes compared to non-LCMM patients, though not statistically significant, indicating that contemporary treatments might overcome the impact of adverse prognostic factors associated with LCMM.

Mousa Thalji, MD: No relevant conflicts of interest to declare.